Navigation Links
Data on VIVUS' QNEXA to be Presented in Six Posters at The Obesity Society's Annual Meeting
Date:10/7/2010

e not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission. CONTACT:   VIVUS, Inc.Investor Relations:Media Relations:Timothy E. MorrisThe Trout GroupGolinHarrisChief Financial Officer

Brian Korb

Susan Brophy650-934-5200

646-378-2923

sbrophy@golinharris.comBKorb@troutgroup.com

312-729-4359
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. ApoA-I Data Presented at European Society of Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015 The Pittcon 2015 ... the Ernest N. Morial Convention Center in New ... of February 19, 2015) displaying products and services ... and government labs. The Exposition will offer the ... limited to, analytical chemistry; drug discovery; nanotechnology; life ...
(Date:2/26/2015)... 2015 Innovation is more urgent ... unexpected parts of the world and transforming global ... to manufacturing to health care, disruption is constantly ... and socio-political trends shake the foundations of established ... for CEOs to survive the next wave of ...
(Date:2/26/2015)... According to a new market report published by ... (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled Products and ... and Forecast, 2013 – 2019,”the global agricultural biotechnology market ... is expected to reach USD 28,694.1 million by 2019, ... 2019. , Demand for food production has increased ...
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Regis ... for the development of oncology drug substances. , Regis ... up of their new Potent Compound Suite (PCS) for ... a 36,000 square foot, cGMP facility in Morton Grove, ... cGMP manufacturing of potent compounds up to about one ...
Breaking Biology Technology:Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2
... UK,s National Physical Laboratory (NPL) is working to provide more ... nanotechnology which could lead to much more accurate devices ... Nobel Prize in 1986. It uses a nano-sized probe to ... finger reading Braille on an extremely small scale. The technique ...
... 20 Deloitte today released the 2010 Technology Fast ... media, telecommunications, life sciences and clean technology companies in ... fiscal year revenue growth from 2005 to 2009.  For ... on the Technology Fast 500™ than any other single ...
... Iowa, Oct. 20 Bio-Research Products announced today ... offerings a lower cost, industrial grade for application ... Dr. Bryce Cunningham, President, said that "there has ... and pharmaceutical markets which has prompted us to ...
Cached Biology Technology:Measuring the electrical properties of nano-crystals 2Deloitte Announces 2010 Technology Fast 500™ Rankings 2Deloitte Announces 2010 Technology Fast 500™ Rankings 3Deloitte Announces 2010 Technology Fast 500™ Rankings 4Bio-Research Products Introduces New Grade of Chloroperoxidase Enzyme for Industrial Applications 2
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... top of the marine food chain, albatrosses accumulate toxic ... bodies. A new study has found dramatic differences in ... forage in different areas of the North Pacific. Researchers ... increased in both species over the past ten years. ...
... When invaded by an infectious agent, for example, the ... and defeat the intruder. But when the biochemical processes ... turned on, inflammation can lead to adversity, including some ... closely studying the link between inflammatory processes and tumor ...
... a future in which each patient's tumor will act ... the cancer to obtain the best outcome. , ... should receive extra therapy after surgery - or whether ... does not even require surgery. Most patients with colorectal ...
Cached Biology News:Vegetables inhibit growth of prostate cancer in mice with human tumors 2Vegetables inhibit growth of prostate cancer in mice with human tumors 3Inflammation and drugs to control this activity studied in a variety of tumors sites 2Inflammation and drugs to control this activity studied in a variety of tumors sites 3Inflammation and drugs to control this activity studied in a variety of tumors sites 4Inflammation and drugs to control this activity studied in a variety of tumors sites 5Inflammation and drugs to control this activity studied in a variety of tumors sites 6Inflammation and drugs to control this activity studied in a variety of tumors sites 7Inflammation and drugs to control this activity studied in a variety of tumors sites 8Inflammation and drugs to control this activity studied in a variety of tumors sites 9AIDS-related cognitive impairment exists in two separate forms 2AIDS-related cognitive impairment exists in two separate forms 3AIDS-related cognitive impairment exists in two separate forms 4AIDS-related cognitive impairment exists in two separate forms 5AIDS-related cognitive impairment exists in two separate forms 6AIDS-related cognitive impairment exists in two separate forms 7
... Immunogen: Synthetic ... 22-37 SGHKSEEKREKMKRTL Antigen Family: ... signalling; Antigen Subfamily: ... signalling Recommended Storage: ...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
...
... The PROTEAN II xi 2-D system runs both ... first-dimension IEF tube gels can be separated in a ... onto the cooling core in much the same manner ... are running, the second-dimension slab gels may be cast ...
Biology Products: